10/538903

International Application No.: PCT/EP2003/014714

International Filing Date: December 22, 2003

Page: 5

JC17 Rec'd PCT/PTO 14 JUN 2005

## **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

## **Patent Claims**

- 1). (Currently Amended) A cholesterol-reducing and triglyceride-reducing food agent comprising water-insoluble carob fiber and at least one n-3 fatty acid, the n-3 fatty acid or the n-3 fatty acids being present at a concentration of at least 15 area % of TFA (area % based on the AOCS Official Method Ce 1b-69; TFA = total fatty acid).
- 2). (Previously Presented) The agent as claimed in claim 1, wherein the n-3 fatty acid is a polyunsaturated fatty acid having a chain length > C12 having at least two double bonds, or its ester, triglyceride, phospholipid, glycolipid, sphingolipid, wax or sterol ester.
- 3). (Currently Amended) The agent as claimed in one of claim[[s]] 1 or 2, wherein the n-3 fatty acid is selected from one or more of the following substances: all-cis-9,12,15-octadecatrienoic acid (ALA), all-cis-6,9,12,15-octadecatetraenoic acid, all-cis-11,14,17-eicosatrienoic acid, all-cis-8,11,14,17-eicosatetraenoic acid, all-cis-5,8,11,14,17-eicosatetraenoic acid, all-cis-7,10,13,16,19-docosapentaenoic acid (EPA), all-cis-13,16,19-docosatrienoic acid, all-cis-7,10,13,16,19-docosapentaenoic acid (DPA) and all-cis-4,7,10,13,16, 19-docosahexaenoic acid (DHA).
- 4). (Previously Presented) The agent as claimed in claim 3, wherein the n-3 fatty acid is all-cis-4,7,10,13,16,19-docosahexaenoic acid (DHA).
- 5). (Previously Presented) A cholesterol-reducing combination preparation comprising water-insoluble carob fiber and at least one n-3 fatty acid in separate administration forms, the n-3 fatty

International Application No.: PCT/EP2003/014714

International Filing Date: December 22, 2003

Page: 6

acid or the n-3 fatty acids being present at a concentration of at least 15 area % of TFA (area % based on the AOCS official method Ce 1b-69; TFA = total fatty acid).

- 6). (Currently Amended) A method for producing an agent as claimed in one of claim[[s]] 1 to 4, which comprises mixing at least one carob product and at least one cholesterol-reducing active compound with one another.
- 7). (Currently Amended) The use of A drug comprising an agent as claimed in one of claim[[s]] 1 to 4 as drug.
- 8). (Currently Amended) The use A drug as claimed in claim 7 as, wherein said drug is a cholesterol-reducing drug.
- 9). (Currently Amended) The use A drug as claimed in claim 7 for the prophylaxis of wherein said drug is a hypercholesterolemia, hyperlipidemia or arteriosclerosis drug.
- 10). (Currently Amended) The use A drug as claimed in claim 7 for the positive shifting of wherein said drug postitively shifts the HDL/LDL ratio.
- 11). (Currently Amended) The use of an An agent as claimed in one of claim[[s]] 1 to 4 for wherein said agent is administered along with an additional supply with n-3 fatty acids.